Regencell Bioscience Holdings Limited (Nasdaq: RGC) is moving higher on March 31, 2026 after the company disclosed an at-the-market (ATM) offering program that allows it to offer and sell up to $500 million of its ordinary shares from time to time. The company said the program is being run through a sales agreement with Univest Securities, LLC, and that it is not obligated to sell any shares under the program.

An ATM can be interpreted in two opposing ways by traders: it can strengthen liquidity access for a pre-revenue issuer, but it can also create an overhang because shares may be sold into market strength. With volatile, thin-float names, incremental supply or the expectation of supply can drive outsized intraday swings—either as a “risk-on” liquidity catalyst or as a dilution fear that whipsaws price action.

Investors will be watching for any indication that sales have begun, the pace of issuance (if any), and whether proceeds are paired with specific operational milestones. The filing also stated intended use of proceeds is primarily working capital, capital expenditures, and general corporate purposes, which typically provides flexibility but limited near-term specificity.